A	O
biodistribution	O
study	B:C2603343
of	O
solid	B:C0013161
lipid	I:C0013161
-	I:C0013161
polyethyleneimine	I:C0013161
hybrid	I:C0013161
nanocarrier	I:C0013161
for	O
cancer	B:C0006826
RNAi	B:C4042855
therapy	I:C4042855
.	O

Solid	B:C0013161
lipid	I:C0013161
-	I:C0013161
polymer	I:C0013161
hybrid	I:C0013161
nanocarrier	I:C0013161
(	O
lipid	B:C0013161
-	I:C0013161
polymer	I:C0013161
hybrid	I:C0013161
nanocarrier	I:C0013161
)	O
was	O
previously	O
reported	O
to	O
achieve	O
high	O
siRNA	B:C1099354
transfection	B:C0040669
efficiency	O
and	O
induce	O
sustained	O
RNAi	B:C1136031
-	O
based	O
chemosensitizing	B:C1527144
effect	I:C1527144
at	O
cellular	O
level	O
.	O

In	O
this	O
study	B:C2603343
,	O
our	O
objectives	O
were	O
to	O
evaluate	O
the	O
in	B:C1515655
vivo	I:C1515655
biodistribution	O
of	O
LPNs	B:C0013161
in	O
a	O
prostate	B:C0600139
cancer	I:C0600139
model	O
and	O
determine	O
the	O
factors	O
that	O
potentially	O
affect	O
tumor	B:C0027651
penetration	O
by	O
LPNs	B:C0013161
.	O

The	O
lipid	B:C0013161
-	I:C0013161
polymer	I:C0013161
hybrid	I:C0013161
nanocarrier	I:C0013161
formulation	B:C0013058
with	O
the	O
highest	O
transfection	B:C0040669
efficiency	O
(	O
64	O
%	O
)	O
and	O
stability	O
was	O
selected	O
for	O
the	O
study	B:C2603343
.	O

Mice	B:C0025929
bearing	O
tumors	B:C0027651
of	O
PC	B:C1513528
-	I:C1513528
3	I:C1513528
Mcells	I:C1513528
were	O
treated	O
with	O
LPNs	B:C0013161
labeled	O
with	O
IR780	B:C2933062
or	O
AF647	B:C3489916
-	O
siRNA	B:C1099354
.	O

Near	B:C4288612
infrared	I:C4288612
imaging	I:C4288612
showed	O
that	O
LPNs	B:C0013161
achieved	O
favorable	O
in	B:C1515655
vivo	I:C1515655
biodistribution	O
with	O
high	O
tumor	B:C0027651
/	O
low	O
organ	B:C0178784
ratios	O
.	O

lipid	B:C0013161
-	I:C0013161
polymer	I:C0013161
hybrid	I:C0013161
nanocarrier	I:C0013161
accumulation	B:C4055506
was	O
also	O
observed	O
in	O
liver	B:C0023884
metastatic	B:C0475358
tissue	I:C0475358
.	O

Result	O
of	O
extravasation	B:C0015376
study	B:C2603343
confirmed	O
that	O
encapsulated	O
siRNA	B:C1099354
molecules	O
were	O
able	O
to	O
escape	O
into	O
the	O
tumor	B:C0475358
tissue	I:C0475358
at	O
the	O
extravascular	B:C0005898
area	I:C0005898
.	O

When	O
lipid	B:C0013161
-	I:C0013161
polymer	I:C0013161
hybrid	I:C0013161
nanocarrier	I:C0013161
levels	O
in	O
large	O
(	O
volume	O
>	O
750	O
m	O
m	O
(	O
3	O
)	O
)	O
and	O
small	O
(	O
<	O
500	O
m	O
m	O
(	O
3	O
)	O
)	O
tumors	B:C0027651
were	O
compared	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
.	O

However	O
,	O
both	O
docetaxel	B:C0246415
pretreatment	O
(	O
72hbefore	O
lipid-	B:C0013161
polymer	I:C0013161
hybrid	I:C0013161
nanocarrier	I:C0013161
)	O
and	O
concurrent	O
docetaxel	B:C0246415
treatment	B:C0087111
significantly	O
enhanced	O
the	O
tumor	B:C0027651
lipid	B:C0013161
-	I:C0013161
polymer	I:C0013161
hybrid	I:C0013161
nanocarrier	I:C0013161
levels	O
by	O
3.9	O
-	O
and	O
3.1	O
-	O
fold	O
,	O
respectively	O
(	O
both	O
p<0.01	O
)	O
.	O

In	O
conclusion	O
,	O
lipid	B:C0013161
-	I:C0013161
polymer	I:C0013161
hybrid	I:C0013161
nanocarrier	I:C0013161
is	O
a	O
promising	O
carrier	B:C0013161
system	I:C0013161
to	O
deliver	O
RNAi	B:C4042855
therapy	I:C4042855
to	O
solid	B:C4282132
malignancies	I:C4282132
that	O
also	O
receive	O
chemotherapy	B:C3665472
.	O

